Subtype
Breast Adenocarcinoma
CI-CAN-00002035Explore in graph →
686 active trials9 approved drugs104 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002035Explore in graph →
Clinical trials
1,713 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (278)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07104266 | Triple Negative Breast Cancer and Celecoxib. Pilot Study | recruiting | Phase 2 | 30 | Université de SherbrookeOTHER | 1 | Aug 5, 2025 | clinicaltrials |
| NCT06358625 | Identification of Risk Factors for Brain Recurrence in Patients With HER2-positive Localised Breast Cancer(CRANIUM) | recruiting | — | 120 | Center Eugene MarquisOTHER | 1 | Aug 1, 2025 | clinicaltrials |
| NCT05035745 | Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START) | recruiting | Phase 1 / Phase 2 | 63 | National University Hospital, SingaporeOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT05491083 | Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer(ComPACT) | recruiting | Phase 1 / Phase 2 | 51 | National University Hospital, SingaporeOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT07073755 | Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, or T-DXd | recruiting | — | 200 | Hunan Cancer HospitalOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
| NCT05722795 | Use of Imatinib to Convert Triple Negative Breast Cancer Into ER-positive Breast Cancer (I-CONIC)(I-CONIC) | recruiting | N/A | 40 | Vastra Gotaland RegionOTHER_GOV | 1 | Jul 9, 2025 | clinicaltrials |
| NCT07047495 | Personalization of External Beam Radiation Therapy in Localised Tumours(MINIONS) | recruiting | — | 35 | European Institute of OncologyOTHER | 1 | Jul 2, 2025 | clinicaltrials |
| NCT06769425 | HS-10502 Combination Treatment in Patients With Advanced Solid Tumors(HS-10502) | recruiting | Phase 1 | 157 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 24, 2025 | clinicaltrials |
| NCT07030569 | RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study(RADIOSPHER2) | recruiting | — | 500 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Jun 22, 2025 | clinicaltrials |
| NCT06991790 | Sacituzumab Govitecan + Toripalimab as First - Line Therapy for Advanced Triple - Negative Breast Cancer and Biomarker Exploration | recruiting | — | 51 | Peking University Cancer Hospital & InstituteOTHER | 1 | May 28, 2025 | clinicaltrials |
| NCT06984250 | Hypofractionated Radiotherapy With Concomitant Tumor Bed Boost for Breast Cancer(HFCBB) | recruiting | — | 315 | National Taiwan University HospitalOTHER | 1 | May 22, 2025 | clinicaltrials |
| NCT06367088 | Cadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Negative Breast Cancer | recruiting | Phase 2 | 27 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | May 20, 2025 | clinicaltrials |
| NCT03201861 | Addition of Cisplatin to Adjuvant Chemotherapy for Early Stage Breast Cancer in High-Risk Women | recruiting | Phase 3 | 762 | RenJi HospitalOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT04947189 | Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer(4CAST) | recruiting | Phase 1 / Phase 2 | 65 | St Vincent's Hospital, SydneyOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT06958627 | The Impact of Intelligent Patient Management Model on Medication Adherence of Pyrotinib Compared to Traditional Patient Management Model: a Prospective, Multicenter, Randomized Controlled Clinical Study(any) | recruiting | Phase 2 / Phase 3 | 964 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 6, 2025 | clinicaltrials |
| NCT06225284 | Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer Patients(ESCALATE) | recruiting | Phase 2 | 124 | National Taiwan University HospitalOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT05535413 | UTD1 Combined With Capecitabine in Metastatic HER2-negative Breast Cancer Patients With Brain Metastases | recruiting | Phase 1 / Phase 2 | 30 | Hunan Cancer HospitalOTHER | 1 | Apr 25, 2025 | clinicaltrials |
| NCT06476119 | OPTImaL:Optimisation of Treatment for Patients With Low Stage Triple-negative Breast Cancer With High Stromal Tumor-infiltrating Lymphocytes(OPTImaL) | recruiting | — | 490 | The Netherlands Cancer InstituteOTHER | 1 | Apr 23, 2025 | clinicaltrials |
| NCT06920810 | Viscum Album for TNBC on Adjuvant Pembrolizumab(TNBNOBA) | recruiting | Phase 4 | 40 | Ilsan Cha hospitalOTHER | 1 | Apr 10, 2025 | clinicaltrials |
| NCT01785420 | Pre Operative Trastuzumab in Operable Breast Cancer | recruiting | Phase 3 | 1,100 | Dr Rajendra A. BadweOTHER_GOV | 1 | Apr 9, 2025 | clinicaltrials |
| NCT05406635 | Imaging Versus Cardiac Biomarker Monitored HER2 Directed Therapy in Patients With Breast Cancer(HER2BIC) | recruiting | N/A | 220 | Odense University HospitalOTHER | 1 | Apr 8, 2025 | clinicaltrials |
| NCT05955170 | Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast Cancer(TUC-TOC) | recruiting | Phase 2 | 66 | Institut CurieOTHER | 1 | Mar 27, 2025 | clinicaltrials |
| NCT03671044 | A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients | recruiting | Phase 3 | 657 | Jina Pharmaceuticals Inc.INDUSTRY | 2 | Mar 21, 2025 | clinicaltrials |
| NCT05485766 | Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer | recruiting | Phase 2 | 23 | Okayama UniversityOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT06877416 | Analysis of Exploring Optimized Sequential Treatment Strategies of Antibody-Drug Conjugates (ADCs) in HER2-Low-Expressing Breast Cancer | recruiting | — | 700 | Sun Yat-sen UniversityOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT06880029 | Circadian Rhythm Impact on TNBC Response to Neoadjuvant Immunotherapy(CIRCADIAN) | recruiting | Phase 1 / Phase 2 | 20 | Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E.OTHER_GOV | 1 | Mar 19, 2025 | clinicaltrials |
| NCT04510129 | A Multicenter Cancer Biospecimen Collection Study | recruiting | — | 1,650 | Cofactor Genomics, Inc.INDUSTRY | 1 | Mar 12, 2025 | clinicaltrials |
| NCT05918328 | Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC | recruiting | Phase 2 | 610 | Henan Cancer HospitalOTHER_GOV | 1 | Mar 7, 2025 | clinicaltrials |
| NCT06851299 | The Clinical Study of the Efficacy and Safety of Trop2-ADC Monotherapy or Combination Immunotherapy Strategy in the Treatment of Advanced Triple-negative Breast Cancer. | recruiting | Phase 2 | 60 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT05020860 | Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer(RESPONSE) | recruiting | Phase 2 | 185 | Baylor Breast Care CenterOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT06832904 | Neoadjuvant Chemotherapy Plus Pyrotinib and Trastuzumab for HER2-positive Breast Cancer (NEOTORCH-BREAST05) | recruiting | Phase 2 | 33 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Feb 18, 2025 | clinicaltrials |
| NCT06671262 | Neoadjuvant Toripalimab and Radiotherapy Treatment in N+ HR+ Breast Cancer(NEOTRIO-HR) | recruiting | Phase 2 | 74 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT06786026 | QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC | recruiting | Phase 2 | 60 | Fudan UniversityOTHER | 1 | Feb 6, 2025 | clinicaltrials |
| NCT06805812 | Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study(PALMARES-2) | recruiting | — | 3,500 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Feb 3, 2025 | clinicaltrials |
| NCT05388149 | Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease | recruiting | Phase 2 | 15 | University Health Network, TorontoOTHER | 1 | Jan 31, 2025 | clinicaltrials |
| NCT05912569 | Delayed Selective Sentinel Node Biopsy for Patients Undergoing Mastectomy for DCIS | recruiting | N/A | 84 | Seoul National University HospitalOTHER | 1 | Jan 31, 2025 | clinicaltrials |
| NCT06793332 | BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC(BALISTA) | recruiting | Phase 2 | 39 | Fudan UniversityOTHER | 1 | Jan 27, 2025 | clinicaltrials |
| NCT05475678 | Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer | recruiting | Phase 2 | 369 | Zhenzhen LiuOTHER_GOV | 1 | Jan 23, 2025 | clinicaltrials |
| NCT06492005 | A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer | recruiting | Phase 2 | 160 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Jan 10, 2025 | clinicaltrials |
| NCT06754059 | Pyrotinib Combined With Trastuzumab for Maintenance Therapy After First-line TH (P) Therapy for HER2+ABC | recruiting | — | 60 | zhangjieOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT06276868 | Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer | recruiting | Phase 2 | 71 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 17, 2024 | clinicaltrials |
| NCT06636981 | All Trans Retinoic Acid Combined with Toripalimab+Chemotherapy for Locally Advanced Inoperable or Metastatic Triple Negative Breast Cancer：a Multi-center, Multi-cohort Phase II Trial | recruiting | Phase 2 | 129 | Fudan UniversityOTHER | 1 | Dec 13, 2024 | clinicaltrials |
| NCT06722599 | Four Cycles Taxane With Trastuzumab and Pertuzumab Neoadjuvant Therapy Among Low Risk HER2 Positive Patients(LRNacHER2) | recruiting | — | 171 | Shu WangOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT06722612 | Chemotherapy Combined With Targeted Therapy for High-risk HER2 Positive and Lymph Node Negative Early Breast Cancer(TaxCbHER2) | recruiting | — | 2,916 | Shu WangOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT06711055 | Taxane Combined Targeted Therapy for Low-risk HER2 Positive and Lymph Node Negative Breast Cancer(TaxHER) | recruiting | — | 285 | Shu WangOTHER | 1 | Dec 2, 2024 | clinicaltrials |
| NCT06711068 | Adjuvant Therapy for Intermediate Risk HER2 Positive, Lymph Node Negative Early Breast Cancer With Chemotherapy Combined Target Therapy(TaxDHER2) | recruiting | — | 8,077 | Shu WangOTHER | 1 | Dec 2, 2024 | clinicaltrials |
| NCT06538896 | Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis，an Exploratory, Single-Arm, Multicenter Phase II Clinical Study | recruiting | Phase 2 | 20 | Zhejiang Cancer HospitalOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT06700369 | De-escalation of Neoadjuvant Chemotherapy Regimens With Targeted Therapy Among HER2 Positive Patients(NacHER2) | recruiting | — | 519 | Shu WangOTHER | 1 | Nov 25, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Aug 5, 2025source: clinicaltrials